VC firm Vivo Capital outlays $740m for biotech investment
Set against a backdrop of barren biotech investment, Vivo Capital has secured $740m to back preclinical and clinical-stage life science…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand
Novo Nordisk has reduced its sales and profits forecasts for 2025 due to lower-than-expected demand in the US for blockbuster…
-
US government exercises $144m option for smallpox/mpox vaccine contract
Amid a US measles outbreak the US government has placed a $143.6m order for Bavarian Nordic’s smallpox/mpox jab Jynneos to…
-
Q1 earnings pulse check: companies tentative on pharma-specific tariffs
While many pharmaceutical companies have calculated cost hits associated with US tariffs, they are reiterating that looming pharma-specific tariffs create…
-
Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off
Biogen has unveiled Q1 2025 revenues above estimates, spurred by strong sales of rare disease assets amid a sales dropoff…
-
New £1bn cancer research hub planned for South London
Plans have been unveiled for The London Cancer Hub, a state-of-the-art cancer research and laboratory hub to be located in…
-
Innorna secures dual FDA designations for Wilson’s disease mRNA therapy
The US Food and Drug Administration (FDA) has granted rare paediatric disease and orphan drug designations for IN013, Innorna's mRNA…
-
FDA free to pursue semaglutide compounders after latest court ruling
A US judge has rejected efforts by a compounded drugs industry group to keep making an alternative version of Novo…
-
Thermo Fisher counters tariffs with $2bn investment into US manufacturing
Thermo Fisher has outlaid $2bn to expand manufacturing and development in the US, joining the long list of companies directing…
-
Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing
Eli Lilly has filed a lawsuit against four telehealth platforms selling compounded versions of its blockbuster metabolic disorder drug tirzepatide,…